TABLE 3

Financial Results For The Second Quarter of 2005
Condensed Consolidated Statements Of Income - Operating Basis
(in millions, except per share amounts)

The non-GAAP financial measures presented below are utilized by Biogen Idec management to gain an understanding of the comparative financial performance of the Company. Management believes that the non-GAAP financial measures are useful because they exclude those non-operational activities or transactions that are not necessarily relevant to understanding the trends of the Company or the prospects of future performance. The presentation of this information is not meant to be considered in isolation or as a substitute for GAAP financial measures. Numbers may not foot due to rounding.

	Three Months Ended June 30,		Six Months Ended June 30,	
	2005	2004	2005	2004
Earnings per share - Diluted:				
GAAP	**$0.10**	**$0.00**	**$0.23**	**($0.12)**
Adjusted Pro Forma (Non-GAAP)	**$0.43**	**$0.34**	**$0.73**	**$0.73**
AN ITEMIZED RECONCILIATION BETWEEN NET INCOME ON A GAAP BASIS AND NET INCOME ON A NON-GAAP BASIS IS AS FOLLOWS:				
GAAP Net Income/(Loss)	$ 34.5	$0.8	$78.0	($40.4)
COGS: Fair value step up of inventory acquired from former Biogen, Inc	9.0	93.4	18.3	287.8
R&D: Costs associated with Sale of Oceanside Manufacturing Facility	1.9	-	1.9	-
R&D: Merger related and purchase accounting costs	-	0.7	-	2.9
SG&A: Merger related and purchase accounting costs	-	0.6	0.4	5.0
Purchase accounting: Amortization of acquired intangible assets related to the merger with former Biogen, Inc.	77.1	79.3	152.8	160.2
Loss on Sale of Oceanside Manufacturing Facility	75.6	-	75.6	-
Income taxes: Income tax effect of reconciling items	(49.0)	(53.2)	(72.1)	(151.2)
Non-GAAP Net Income	$ 149.0	$ 121.7	$ 254.8	$ 264.3

Adjustments were made to conform prior periods to current year presentation including adoption of EITF 03-06, which requires allocation of income to certain holders of equity and debt instruments.